Beigene Ltd (NASDAQ:BGNE) has been given a consensus recommendation of “Buy” by the fourteen research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $178.72.
Several research analysts recently commented on the company. Cowen reaffirmed a “buy” rating on shares of Beigene in a research report on Sunday, October 14th. Leerink Swann began coverage on Beigene in a research report on Monday, September 24th. They issued an “outperform” rating and a $215.00 target price for the company. BidaskClub lowered Beigene from a “sell” rating to a “strong sell” rating in a research note on Monday, October 15th. Maxim Group reiterated a “buy” rating and set a $215.00 price objective on shares of Beigene in a research note on Thursday, September 20th. Finally, CLSA began coverage on Beigene in a research note on Wednesday, September 19th. They set a “buy” rating and a $160.75 price objective for the company.
In other news, CMO Amy C. Peterson sold 40,000 shares of the firm’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $120.20, for a total value of $4,808,000.00. Following the completion of the sale, the chief marketing officer now directly owns 194,569 shares in the company, valued at $23,387,193.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John Oyler sold 29,195 shares of the firm’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $143.66, for a total value of $4,194,153.70. Following the completion of the sale, the chief executive officer now owns 17,420,172 shares of the company’s stock, valued at $2,502,581,909.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 130,122 shares of company stock valued at $17,156,904. 13.30% of the stock is currently owned by corporate insiders.
BGNE stock opened at $144.25 on Friday. Beigene has a one year low of $95.34 and a one year high of $220.10. The stock has a market cap of $8.48 billion, a price-to-earnings ratio of -64.69 and a beta of 1.70. The company has a quick ratio of 11.47, a current ratio of 11.57 and a debt-to-equity ratio of 0.09.
Beigene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($2.53) earnings per share for the quarter, beating the consensus estimate of ($2.97) by $0.44. Beigene had a negative return on equity of 38.44% and a negative net margin of 320.08%. The company had revenue of $54.20 million during the quarter, compared to analysts’ expectations of $47.06 million. During the same period in the prior year, the business earned $2.54 earnings per share. Beigene’s revenue for the quarter was down 75.4% compared to the same quarter last year. Sell-side analysts predict that Beigene will post -10.09 EPS for the current year.
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Featured Story: How accurate is the Rule of 72?
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.